Therapeutic Advancements in Multiple Myeloma
| Autor: | Alessandro Gozzetti, Giulia Papini, Monica Bocchia, Veronica Candi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Mini Review Myeloma Pharmacology lcsh:RC254-282 elderly IMID’s chemistry.chemical_compound Internal medicine hemic and lymphatic diseases medicine new therapies Lenalidomide Multiple myeloma therapy Bortezomib business.industry young bortezomib multiple myeloma Complete remission Pomalidomide medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Carfilzomib Thalidomide Transplantation chemistry business medicine.drug |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 4 (2014) |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2014.00241 |
| Popis: | Multiple myeloma survival has significantly improved in latest years, due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib and lenalidomide together with autologous stem cell transplantation has dramatically prolonged complete remissions rate, progression free survivals resulting ultimately in prolonged survivals in myeloma patients. Moreover, novel strategies of treatment such as consolidation and maintenance are being used to implement responses. A number of new drugs such as carfilzomib and pomalidomide are already in clinical practice, and new kids on the block are entering, making the future of myeloma patients brighter. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|